Levi & Korsinsky reminds Zoetis Inc. investors of the July 27, 2026 lead plaintiff deadline in a pending securities class action. The lawsuit covers purchases between January 14, 2025 and May 6, 2026, alleging the company concealed FDA safety warnings affecting Librela, market share losses to lower-priced competitors for Simparica Trio, and erosion in its dermatology franchise. Zoetis shares fell 21.5% on May 7, 2026 after the full scope of deterioration was disclosed. Institutional investors with large losses may seek lead plaintiff appointment, which carries no additional financial obligation and provides direct oversight of litigation strategy.
Zoetis IncLawsuit alleges Zoetis concealed FDA safety warnings for Librela, leading to a 21.5% share drop.